Post

Risk adjusted net present value: What is the current valuation of Legend Biotech’s LB-1908?

LB-1908 is a gene-modified cell therapy commercialized by Legend Biotech, with a leading Phase I program in Adenocarcinoma Of The …

Risk adjusted net present value: What is the current valuation of Celltrion’s Tocilizumab biosimilar?

Tocilizumab biosimilar is a monoclonal antibody commercialized by Celltrion, with a leading Phase III program in Rheumatoid Arthritis. According to …

Risk adjusted net present value: What is the current valuation of AstraZeneca’s Puxitatug Samrotecan?

Puxitatug Samrotecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase II program in Metastatic Bile Duct …

Risk adjusted net present value: What is the current valuation of Amgen’s Ustekinumab Biosimilar?

Ustekinumab Biosimilar is a monoclonal antibody commercialized by Amgen, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris). …

Risk adjusted net present value: What is the current valuation of Gracell Biotechnologies’s GC-012F?

GC-012F is a gene-modified cell therapy commercialized by Gracell Biotechnologies, with a leading Phase II program in Relapsed Multiple Myeloma. …